How would you manage a patient with Stage IV Non-small Cell Lung Cancer with concomitant atypical EGFR mutation (such as G719D) and atypical ROS1 fusion?

Topics: Thoracic Malignancies • Medical Oncology

Would you attempt targeted therapy or would you choose chemo-immunotherapy?

Answer from: Medical Oncologist at Academic Institution

Short answer: I would start with afatinib or osimertinib. Tumors with rare EGFR sensitizing mutations, such as G719X, are responsive to EGFR TKIs, though they appear to have somewhat lower RR and duration of response than tumors with common mutations. Afatinib is the only agent FDA-approved for the...

Related Questions